CLINICAL TRIALS

UPDATES AND ADDITIONS

*To update or add a clinical trial, please e-mail **HDInsights@hsglimited.org**.*

	SPONSOR	IDENTIFIER	AGENT	PHASE	DESIGN	SITES
CURRENTLY ENROLLING	Sage Therapeutics	SAGE-718	718-CLP-102 B	I	A Phase 1, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Healthy Adults With an Open-label Cohort of Patients With Huntington's Disease	Long Beach, CA and Berlin, NJ
	Roche/ Genentech	GENERATION HD1	RG6042	III	A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease	30 Total: United States and Canada 19 Total: Europe
	Wave Life Sciences Ltd.	PRECISIONHD-1 PRECISIONHD2	WVE-120101 WVE-120102	I / II	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 and WVE-120102 Administered Intrathecally in Patients With Huntington's Disease	5 Total: Canada and Europe
	Ultragenyx Pharmaceutical	TRIHEP3	Triheptanoin oil	II	A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease	2 Total: France and Netherlands
	Azidus Brasil	ADORE-DH	Cellavita	II	Dose-Response Evaluation of the Investigational Product Cellavita HD After Intravenous Administration in Patients With Huntington's Disease	Sao Paulo, Brazil
ACTIVE	Vaccinex, Inc.	SIGNAL	VX15/2503	II	A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503	30 Total: United States and Canada
	Azevan Pharmaceuticals	AVN011	SRX246	I / II	An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)	22 Total: United States
RECENTLY COMPLETED	Teva Pharmaceutical Industries	OPEN-HART	Pridopidine	II	A Multi-Center, North American, Open-Label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington's Disease (Open-HART)	12 Total: United States and Canada
	Teva Pharmaceutical Industries	LEGATO-HD	Laquinimod	II	A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as Treatment in Patients With Huntington's Disease	52 Total: Worldwide

Sources: www.clinicaltrials.gov and apps.who.int/trialsearch

HD THERAPEUTIC PIPELINE

TREATMENT TYPE

- Disease-modifying therapies
- Symptomatic treatments
- Gene-targeting therapies

Sources: www.clinicaltrials.gov, HDSA's Therapies in the Pipeline, and company/developer websites.

To patients

- Deutetrabenazine (Teva)
- Tetrabenazine (Lundbeck)

Phase 3

- RG6042 (Roche/Genentech)

Phase 2

- WVE-120101 (Wave Life Sciences)
- WVE-120102 (Wave Life Sciences)
- SRX246 (Azevan Pharmaceuticals)
- VX15/2503 (Vaccinex)

Phase 1

- VY-HTT01 (Voyager Therapeutics)
- AMT-130 (uniQure)
- SAGE-718 (Sage Therapeutics)

Preclinical

- PTC small molecule (PTC Therapeutics)
- MTC-1203 (Mitoconix)